Jorge Nieva

Professor of Clinical Medicine

University of Southern California
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (39)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Background: Survivors of adolescent and young adult (AYA, ages 15–39 years at diagnosis) cancer are at increased risk for subsequent malignant neoplasms (SMN), of which lung cancer is the most lethal. Factors contributing to lung SMN development and outcomes are not well characterized. Methods: Survivors of AYA cancer diagnosed between 1998 and 2020 were identified in the California Cancer Registry (n = 251,632). Pearson’s χ2 and Fisher’s exact tests were used to determine associations between sociodemographic and cancer characteristics and SMN status. Multivariable Cox proportional hazard regression, adjusting for age, time from primary diagnosis, race/ethnicity, insurance, primary cancer site, stage, and treatment, evaluated associations between these characteristics and the incidence and mortality of lung cancer as first SMN. Results: A total of 675 (0.7%) survivors were diagnosed with lung SMN, of whom 487 (72.1%) died. The median time from primary diagnosis to lung SMN was 13.0 years (IQR 4.0–20.0 years). Nearly half (46.5%) of survivors with lung SMN had metastatic disease. Non-Hispanic Black survivors were more likely than non-Hispanic White survivors to develop lung SMN [adjusted HR (aHR) = 1.47; 95% confidence interval (95% CI), 1.13–1.91] but were not more likely to die from lung SMN (aHR = 0.84; 95% CI, 0.56–1.27). Primary cancer treatment with both chemotherapy and radiation was associated with a greater likelihood of lung SMN (aHR = 1.41; 95% CI, 1.11–1.80) compared with receiving neither. Conclusions: Lung SMN has a long latency and high mortality among survivors of AYA cancer. Impact: More research is needed on lung cancer prevention, education, and early detection, particularly among survivors at higher risk.

Year:

2025

Background Recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) has a high recurrence rate after first-line immunotherapy or chemoimmunotherapy. The presence of a high density of tumor-infiltrating lymphocytes (TILs) in HNSCC tumors was shown to be associated with improved clinical outcomes. One-time autologous TIL cell therapy was evaluated in patients with recurrent and/or metastatic HNSCC. Methods C-145-03 ( NCT03083873 ) was a phase 2 study of TIL in patients with recurrent and/or metastatic HNSCC assigned to 1 of 4 treatment cohorts: cohort 1, non-cryopreserved TIL; cohort 2, cryopreserved lifileucel (22-day manufacturing); cohort 3, cryopreserved lifileucel (16-day manufacturing); cohort 4, cryopreserved LN-145-S1 programmed cell death protein-1 (PD-1) selected. Patients underwent tumor resection for TIL generation. After preparative non-myeloablative lymphodepletion, patients received a single infusion of TIL followed by interleukin-2 (IL-2) infusion(s). The primary endpoint was investigator-assessed objective response rate (ORR) per Response Evaluation Criteria for Solid Tumors (RECIST) V.1.1. Secondary endpoints were investigator-assessed duration of response (DOR), disease control rate (DCR), progression-free survival, overall survival, and incidence of treatment-emergent adverse events. Results Overall, 53 patients received TIL: cohort 1 (n=8), cohort 2 (n=17), cohort 3 (n=16), cohort 4 (n=12). Median age was 57 years and most patients were males (87%; 46/53) with stage IV disease (98%; 52/53). Patients had a median of two prior lines of systemic therapy; 87% (46/53) of patients had prior anti-PD-1/programmed cell death ligand-1 therapy and 72% (38/53) had prior chemotherapy. The ORR was 11% (6/53) with six patients achieving partial response (cohort 1, n=3; cohort 2, n=1; cohort 4, n=2). At median follow-up of 17.9 months, the median DOR was 7.6 months. The DCR was 76% (40/53); 64% (34/53) of patients had stable disease. The safety profile was consistent with known toxicities associated with non-myeloablative lymphodepletion and IL-2 administration. Conclusions This study demonstrated the feasibility of consistently generating sufficient TIL from HNSCC tumors. Results from this study suggest TIL cell therapy may serve as a potential treatment option for patients with HNSCC and support further development, including TIL cell therapy combined with immune checkpoint inhibitors or other agents or with other TIL products. Trial registration number NCT03083873 .

Year:

2025

Race and ethnicity affect the distribution of molecular alterations seen in patients with non–small cell lung cancer (NSCLC). Although anaplastic lymphoma kinase (ALK) alterations are known to occur in 4% to 5% of the population, data specific to the Hispanic population remain limited. This study describes the real-world incidence of ALK alterations in Hispanic patients with NSCLC treated at a large academic institution in Los Angeles, California, United States, to further elucidate the underlying factors that shape differences in mutational profiles. A total of 607 patients with NSCLC treated at Los Angeles General Medical Center (n = 172) and the University of Southern California Norris Comprehensive Cancer Center (n = 435) who received comprehensive genomic profiling were evaluated from January 2015 to June 2023. The Fisher exact test and multivariate logistic regression were incorporated for statistical analysis. Hispanic patients exhibited a higher incidence of ALK alterations (12.76%, n = 18/141) than non-Hispanic patients (5.36%, n = 23/466; P = 0.0046). Multivariate logistic regression showed that Hispanic ethnicity (HR, 2.393; 95% confidence interval, 1.115–5.092) and age at diagnosis (HR, 0.9325; 95% confidence interval, 0.9081–0.9558) were significant variables in ALK alteration incidence, and 55.81% (n = 24) of ALK alterations were initially found via comprehensive genomic profiling. This study highlights a significantly higher incidence of ALK alterations among Hispanic patients with NSCLC, emphasizing the impact of race and ethnicity on molecular alterations. Future research is required to evaluate this trend in a larger, more diverse cohort and investigate the roles of environmental factors and tumor microenvironments in influencing ALK alteration prevalence. Significance: This study identified a higher incidence of ALK alterations in Hispanic patients with NSCLC (12.76%) compared with that in non-Hispanic patients (5.36%) treated at a large academic center in Los Angeles, highlighting the impact of race on molecular alteration profiles and emphasizing the need to increase access to molecular analyses for this population. The variability in mutational alterations may be influenced by biological and environmental factors.

Year:

2025

Background: Survivors of adolescent and young adult (AYA, ages 15–39 years at diagnosis) cancer are at increased risk for subsequent malignant neoplasms (SMN), of which lung cancer is the most lethal. Factors contributing to lung SMN development and outcomes are not well characterized. Methods: Survivors of AYA cancer diagnosed between 1998 and 2020 were identified in the California Cancer Registry ( n = 251,632). Pearson’s χ 2 and Fisher’s exact tests were used to determine associations between sociodemographic and cancer characteristics and SMN status. Multivariable Cox proportional hazard regression, adjusting for age, time from primary diagnosis, race/ethnicity, insurance, primary cancer site, stage, and treatment, evaluated associations between these characteristics and the incidence and mortality of lung cancer as first SMN. Results: A total of 675 (0.7%) survivors were diagnosed with lung SMN, of whom 487 (72.1%) died. The median time from primary diagnosis to lung SMN was 13.0 years (IQR 4.0–20.0 years). Nearly half (46.5%) of survivors with lung SMN had metastatic disease. Non-Hispanic Black survivors were more likely than non-Hispanic White survivors to develop lung SMN [adjusted HR (aHR) = 1.47; 95% confidence interval (95% CI), 1.13–1.91] but were not more likely to die from lung SMN (aHR = 0.84; 95% CI, 0.56–1.27). Primary cancer treatment with both chemotherapy and radiation was associated with a greater likelihood of lung SMN (aHR = 1.41; 95% CI, 1.11–1.80) compared with receiving neither. Conclusions: Lung SMN has a long latency and high mortality among survivors of AYA cancer. Impact: More research is needed on lung cancer prevention, education, and early detection, particularly among survivors at higher risk.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (45)

Fumito Ito

Professor

University of Southern California

UNITED STATES
View details

Suresh Ramalingam

Professor, Director of Medical Oncology

Emory University

UNITED STATES
View details

Arthi Sridhar

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

David Carbone

Ohio State University Medical Center

UNITED STATES
View details

Steven R. Grossman

University of Southern California

UNITED STATES
View details

Sachin Pai

Assistant Professor

University of South Alabama

UNITED STATES
View details

Niels C. Kokot

University of Southern California

UNITED STATES
View details

Hirva Mamdani

Karmanos Cancer Institute

UNITED STATES
View details

Stephen Liu

Associate Professor

Georgetown University School of Medicine

UNITED STATES
View details

Enakshi Saha

Assistant Professor

University of South Carolina

UNITED STATES
View details

Camila Lopes-Ramos

Harvard University

UNITED STATES
View details

Misako Nagasaka

University of California Irvine School of Medicine

UNITED STATES
View details

Yueh-Yun Chi

Research Professor

University of Southern California

UNITED STATES
View details

Balazs Halmos

Montefiore Medical Center

UNITED STATES
View details

Ari VanderWalde

Global Head of Clinical Trials

-

UNITED STATES
View details

David J. Pinato

Imperial College London

UNITED KINGDOM
View details

Richard A. Flavell

Yale University School of Medicine

UNITED STATES
View details

Ming Li

Professor

University of Southern California

UNITED STATES
View details

John Quackenbush

Professor of Computational Biology and Bioinformatics

Harvard T.H. Chan School of Public Health

UNITED STATES
View details

Brahm Segal

Chair

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Ryutaro Kajihara

Kumamoto University

JAPAN
View details

Chul Kim

Georgetown University

UNITED STATES
View details

Misty Shields

Assistant Professor

Indiana State University

UNITED STATES
View details

Miguel Mosteiro Lamas

Institut Català d'Oncologia

SPAIN
View details

Alessio Cortellini

Imperial College London

UNITED KINGDOM
View details

Hisashi Harada

Virginia Commonwealth University

UNITED STATES
View details

Sylvia Lee

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

David R. Freyer

-

UNITED STATES
View details

Angelina Lim

University of Southern California

UNITED STATES
View details

Hossein Borghaei

Professor and Chief, Thoracic Oncology

Fox Chase Cancer Center

UNITED STATES
View details

Rom Leidner

-

UNITED STATES
View details

Michael Roth

Associate Professor of Pediatrics

The University of Texas MD Anderson Cancer Center Children's Cancer Hospital

UNITED STATES
View details

Caryn Lerman

University of Southern California

UNITED STATES
View details

Swati Palit Deb

Professor

Virginia Commonwealth University

UNITED STATES
View details

Eziafa Oduah

Assistant Professor

Duke University

UNITED STATES
View details

Amin Nassar

Yale University

UNITED STATES
View details

Robert Ferris

UPMC Endowed Professor

University of Pittsburgh School of Medicine

UNITED STATES
View details

Ana I Velazquez

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Junko Matsuzaki

Research Professor

University of Chicago

UNITED STATES
View details

sumitra deb

Virginia Commonwealth University

UNITED STATES
View details

Senthil K. Radhakrishnan

Virginia Commonwealth University

UNITED STATES
View details

Luis E. Raez

-

UNITED STATES
View details

Jun Zhang

Professor

University of Kansas Medical Center

UNITED STATES
View details

ENRIQUETA FELIP

Head Thoracic Oncology Unit (After Competitive Exam)

Hospital Universitari Vall d'Hebron

SPAIN
View details

Jennifer Koblinski

Assistant professor, Director Cancer Mouse Models Core

Virginia Commonwealth University

UNITED STATES
View details